Please login to the form below
progressive supranuclear palsy
This page shows the latest progressive supranuclear palsy news and features for those working in and with pharma, biotech and healthcare.
Roche pays $120m upfront for UCB’s anti-tau Alzheimer’s drug
The investigational treatment, UCB0107, is a monoclonal antibody drug being developed by UCB as a potential treatment for patients with tauopathies, such as progressive supranuclear palsy (PSP) and Alzheimer’s disease. ... Tau pathology is indicated in
Latest news
-
Biogen grows in Q2, but Spinraza performance a concern
Biogen has a number of significant clinical readouts over the next 18 months, but many of these remain high risk, such as the phase 3 trial of BIIB092 in progressive supranuclear ... palsy. One big binary decision awaiting the firm is a challenge
-
Spinraza keeps Biogen afloat as Tecfidra stalls
He adds: “By the end of 2020 we expect readouts across our clinical programmes in MS, progressive supranuclear palsy, ALS, Parkinson’s disease, pain, cognitive impairment associated with schizophrenia, epilepsy, stroke, ... Trial results of
-
Spinraza lifts Biogen ahead of Alzheimer’s data
enrolment in phase 2 studies of new MS therapy opicinumab and BIIB092 for progressive supranuclear palsy.
-
Celgene bulks up pipeline again with $2.1bn Prothena deal
The three targets at the centre of the collaboration with Ireland-based Prothena include: tau protein, already a focus in Alzheimer’s research and other conditions like progressive supranuclear palsy (PSP);
-
AbbVie takes anti-tau drug into phase II for Alzheimer's
drugs. The antibody - called ABBV-8E12 - is being tested in two phase II trials, one in patients with early Alzheimer's and a second in progressive supranuclear palsy (PSP), a rare ... We see potential in ABBV-8E12 and tau-focused approaches to
Biogen grows in Q2, but Spinraza performance a concern
Spinraza lifts Biogen ahead of Alzheimer’s data
Celgene bulks up pipeline again with $2.1bn Prothena deal
AbbVie takes anti-tau drug into phase II for Alzheimer's
More from news
Approximately 1 fully matching, plus 8 partially matching documents found.
Latest Intelligence
-
Deal Watch - May 2017
BMS. Biogen (US). Licence. Anti-tau antibody pre phase 2 for progressive supranuclear palsy.
-
Deal Watch table for April 2014
750. iPerian/ BMS. Acquisition. CNS/ Tauopathies, mAB IPN007 to treat progressive supranuclear palsy (PSP) (preclinical).
Deal Watch - May 2017
Deal Watch table for April 2014
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Editor & Senior Editor - Medical Communications - Home Based
-
Highly Competitive Salary, Bonus &Benefits
-
Digital project manager
-
Competitive
-
Events Executive
-
Depending on Experience
- Senior Account Director & Associate Director - Healthcare Ad...
-
Highly Competitive Salary, Bonus &Benefits
- Principal/ Senior/ Medical Writer – Global Med Ed and Comms Agen...
-
Highly competitive salary
- FREELANCE (Outside IR35) Opportunities for this week below!!!
-
Superb Day Rate
- Home Working Medical Copy Writer & Senior Medical Copy Write...
-
Highly Competitive Salary, Bonus &Benefits
- Account Manager - Healthcare Consultancy
-
Salary depending on experience
-
Digital account director
-
Competitive
- FREELANCE Medical Writer, Senior Medical Writer, Principal Medic...
-
Highly Competitive Day Rate, Bonus &Benefits
- Client Services Director +, Remote or London – Leadership Opport...
-
Highly Competitive Salary, Bonus &Benefits
-
Digital strategist
-
Competitive
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
- Bayer’s BlueRock Therapeutics gains FDA fast track for Parkinson’s disease cell therapy
- Israel study suggests Pfizer/BioNTech vaccine is less effective against Delta variant
- Novavax announces further delays for regulatory filings of COVID-19 vaccine
- bluebird bio to restart marketing of Zynteglo in EU after previous suspension
- Top 10 ways to leverage the Impetus InSite Platform® to (virtually) launch your brand
- Another Landmark Lucid Workiversary
- Amgen pays $900m upfront to acquire Teneobio’s antibody assets, R&D technologies
- Biogen and Eisai present new data for controversial Alzheimer's drug Aduhelm at AAIC
- AZ publishes new real-world safety data for COVID-19 vaccine Vaxzevria
- Recruiting patients for real-world studies – the power of a digital campaign
- EU approves bluebird bio’s CALD gene therapy Skysona
- Onyx Health Launch Creative Studio After Record Year
- BioNTech plans acquisition of Kite’s TCR cell therapy R&D platform
- FDA advisory committee votes against approval of AZ, FibroGen's roxadustat
- This month in 1939: How dead cattle led to the discovery of warfarin
- Recruiting patients for real-world studies – the power of a digital campaign
PMHub
Bedrock Healthcare Communications
Bedrock Healthcare Communications is an award-winning, independent agency founded in 2011. We partner with healthcare professionals, patients, and global pharmaceutical...
Latest intelligence
- Top 10 ways to leverage the Impetus InSite Platform® to (virtually) launch your brand
- The Impetus InSite Platform® can be used to facilitate virtual and hybrid engagement at all stages of the product lifecycle. Here, we share 10 of the most popular ways to...
- Employee wellbeing in creative agencies: three tips to get you started
- Paul Hutchings, founder of fox&cat, and new friend, Welfy, a workplace wellbeing training firm, discuss the importance of collaboration...
- Managing unhelpful pressure in your creative agency: the human approach
- Paul Hutchings, founder of fox&cat, answers the questions: what does it mean to be human in 2021? Are we putting ourselves under too much pressure?...
